Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73

被引:0
作者
Ross J. Turner
Nicholas J. Geraghty
Jonathan G. Williams
Diane Ly
Daniel Brungs
Martin G. Carolan
Thomas V. Guy
Debbie Watson
Jeremiah F. de Leon
Ronald Sluyter
机构
[1] Illawarra Health and Medical Research Institute,Molecular Horizons and School of Chemistry and Molecular Bioscience
[2] University of Wollongong,Illawarra Cancer Care Centre
[3] CONCERT - Centre for Oncology Education and Research Translation,GenesisCare
[4] Wollongong Hospital,undefined
[5] St Vincent’s Clinic,undefined
来源
Purinergic Signalling | 2020年 / 16卷
关键词
Ecto-enzymes; Purinergic signalling; Purinergic receptor; Liquid biopsy;
D O I
暂无
中图分类号
学科分类号
摘要
CD39 and CD73 are ecto-nucleotidases present on human peripheral blood mononuclear cells (PBMCs) and are emerging biomarkers on these cells in various disorders including cancer. Many factors influence PBMC quality, so it is essential to validate sample processing methods prior to incorporation in clinical studies. This study examined the impact of both PBMC cryopreservation and PBMC isolation using SepMate density gradient centrifugation on CD39 and CD73 expressing subsets. First, PBMCs were isolated from the peripheral blood of 11 healthy donors by routine Ficoll-Paque density gradient centrifugation, cryopreserved and compared with freshly isolated PBMCs by flow cytometry. The proportions of T and B cells expressing combinations of CD39 and CD73 were relatively stable over 6-month cryopreservation, although some T cell combinations revealed small but significant changes. Second, peripheral blood was collected from six healthy donors to compare PBMCs isolated by SepMate or Ficoll-Paque density gradient centrifugation. Compared with Ficoll-Paque, the more rapid SepMate method yielded 9.1% less PBMCs but did not alter cell viability or proportions of T and B cells expressing combinations of CD39 and CD73. The present study reveals that cryopreservation is suitable for studying T and B cells expressing combinations of CD39 and CD73. However, caution should be exercised when observing small differences in these cryopreserved subsets between different cohorts. Further, SepMate and Ficoll-Paque methods of PBMC isolation show similar results for T and B cell subset analysis; however, SepMate is a faster and easier approach.
引用
收藏
页码:389 / 401
页数:12
相关论文
共 302 条
[1]  
Robson SC(2006)The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance Purinergic Signal 2 409-430
[2]  
Sévigny J(2008)Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade Biochim Biophys Acta 1783 673-694
[3]  
Zimmermann H(2010)Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis Proc Natl Acad Sci U S A 107 1547-1552
[4]  
Yegutkin GG(2019)Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies Cell Rep 27 2411-2425
[5]  
Stagg J(2012)Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury PLoS One 7 597-610
[6]  
Divisekera U(2019)Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease Immunol Cell Biol 97 397-410
[7]  
McLaughlin N(2020)A single-nucleotide polymorphism in the human ENTPD1 gene encoding CD39 is associated with worsened graft-versus-host disease in a humanized mouse model Immunol Cell Biol 98 91-96
[8]  
Sharkey J(2011)CD39/adenosine pathway is involved in AIDS progression PLoS Path 7 1441-1448
[9]  
Pommey S(2018)Immune signatures predicting responses to immunomodulatory antibody therapy Curr Opin Immunol 51 191-200
[10]  
Denoyer D(2018)Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab Nat Med 24 1271-1279